Aardvark Therapeutics, Inc. (AARD) › Cash & EquivalentsAardvark Therapeutics, Inc. (AARD) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2024: $61.64M2025: $47.05M$47.05M2024Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$47.05M-23.7%2024$61.64M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share